Early neurological deterioration in acute ischemic stroke patients after intravenous thrombolysis with alteplase predicts poor 3-month functional prognosis - data from the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China)

Table 3 Outcomes after intravenous thrombolysis in END group versus non-END group

Outcomes	No. (%) of patients		Unadjusted OR (95% CI)	P value	Adjusted OR (95% CI)^a	P value
Outcomes	END group (n = 81)	non-END group (n = 1026)	Unadjusted OR (95% CI)	P value	Adjusted OR (95% CI)^a	P value
Primary outcome
mRS 3–6 at 3 months	66(83.54)	376(37.41)	8.49(4.62–15.60)	< 0.0001	8.25(3.77–18.03)	< 0.0001
Safety outcomes
SICH (SITS-MOST)	15(18.52)	1(0.10)	232.83(−)	< 0.0001	109.77(−)	0.001
SICH (ECASS II)	30(37.04)	5(0.49)	120.12(44.74–322.50)	< 0.0001	90.46(19.84–412.44)	< 0.0001
SICH (NINDS)	30(37.04)	22(2.14)	26.84(14.47–49.79)	< 0.0001	12.53(5.15–30.49)	< 0.0001
Mortality at 7	26(32.50)	16(1.56)	30.39(15.39–60.01)	< 0.0001	20.92(7.45–58.72)	< 0.0001
Mortality at 3 months	36(45.00)	59(5.86)	13.13(7.86–21.94)	< 0.0001	8.06(3.91–16.62)	< 0.0001

^aAdjusted baseline variables: prior stroke/TIA, Systolic BP before thrombolysis, Diastolic BP before thrombolysis, glucose before thrombolysis, FBG before thrombolysis, Systolic BP at 2 hours after thrombolysis, Diastolic BP at 2 hours after thrombolysis, LDL after thrombolysis, TC after thrombolysis, Aspirin use within 7 days after thrombolysis, clopidogrel use within 7 days after thrombolysis, OCSP subtypes
Abbreviations: mRS modified Rankin Scale, SICH symptomatic intracranial hemorrhage, SITS-MOST safe implementation of treatments in stroke-monitoring, ECASS II second European–Australasian acute stroke study, NINDS National Institute of Neurological Disorders and Stroke

ISSN: 1471-2377